295 related articles for article (PubMed ID: 26293650)
1. TBK1 inhibitors: a review of patent literature (2011 - 2014).
Yu T; Yang Y; Yin DQ; Hong S; Son YJ; Kim JH; Cho JY
Expert Opin Ther Pat; 2015; 25(12):1385-96. PubMed ID: 26293650
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in small molecule TBK1 inhibitors: a patent review (2015- 2020).
Thomson DW; Bergamini G
Expert Opin Ther Pat; 2021 Sep; 31(9):785-794. PubMed ID: 33724136
[No Abstract] [Full Text] [Related]
3. A review on the role of TANK-binding kinase 1 signaling in cancer.
Alam M; Hasan GM; Hassan MI
Int J Biol Macromol; 2021 Jul; 183():2364-2375. PubMed ID: 34111484
[TBL] [Abstract][Full Text] [Related]
4. Targeting TANK-binding kinase 1 (TBK1) in cancer.
Revach OY; Liu S; Jenkins RW
Expert Opin Ther Targets; 2020 Nov; 24(11):1065-1078. PubMed ID: 32962465
[TBL] [Abstract][Full Text] [Related]
5. A FGFR1 inhibitor patent review: progress since 2010.
Yu T; Yang Y; Liu Y; Zhang Y; Xu H; Li M; Ponnusamy M; Wang K; Wang JX; Li PF
Expert Opin Ther Pat; 2017 Apr; 27(4):439-454. PubMed ID: 27976968
[TBL] [Abstract][Full Text] [Related]
6. Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
Musumeci F; Sanna M; Grossi G; Brullo C; Fallacara AL; Schenone S
Curr Med Chem; 2017; 24(19):2059-2085. PubMed ID: 28266267
[TBL] [Abstract][Full Text] [Related]
7. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases.
Wang T; Block MA; Cowen S; Davies AM; Devereaux E; Gingipalli L; Johannes J; Larsen NA; Su Q; Tucker JA; Whitston D; Wu J; Zhang HJ; Zinda M; Chuaqui C
Bioorg Med Chem Lett; 2012 Mar; 22(5):2063-9. PubMed ID: 22305584
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
9. BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest.
Bai LY; Chiu CF; Kapuriya NP; Shieh TM; Tsai YC; Wu CY; Sargeant AM; Weng JR
Eur J Pharmacol; 2015 Dec; 769():287-96. PubMed ID: 26607461
[TBL] [Abstract][Full Text] [Related]
10. Pim kinase inhibitors: a survey of the patent literature.
Morwick T
Expert Opin Ther Pat; 2010 Feb; 20(2):193-212. PubMed ID: 20100002
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
[TBL] [Abstract][Full Text] [Related]
13. Selective PI3Kδ inhibitors, a review of the patent literature.
Norman P
Expert Opin Ther Pat; 2011 Nov; 21(11):1773-90. PubMed ID: 22017414
[TBL] [Abstract][Full Text] [Related]
14. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
15. Itk inhibitors: a patent review.
Lo HY
Expert Opin Ther Pat; 2010 Apr; 20(4):459-69. PubMed ID: 20218931
[TBL] [Abstract][Full Text] [Related]
16. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
17. Identification and further development of potent TBK1 inhibitors.
Richters A; Basu D; Engel J; Ercanoglu MS; Balke-Want H; Tesch R; Thomas RK; Rauh D
ACS Chem Biol; 2015 Jan; 10(1):289-98. PubMed ID: 25540906
[TBL] [Abstract][Full Text] [Related]
18. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
19. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and opportunities.
Alam M; Ansari MM; Noor S; Mohammad T; Hasan GM; Kazim SN; Hassan MI
Int J Biol Macromol; 2022 May; 207():1022-1037. PubMed ID: 35358582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
